Suppr超能文献

用于IV期前列腺癌手术去势的简单保留附睾睾丸切除术

Simple and Epididymal-Sparing Orchiectomy for Surgical Castration in Stage IV Prostate Cancer.

作者信息

Travis Harrison, Dubic Michael, Bardot Joseph, Edwards Blane, Gills Jessie R, Delacroix Scott E, LaCour Stephen, Mutter Matthew, Bell Donald, Westerman Mary E

机构信息

School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA.

Department of Urology, Louisiana State University Health Sciences Center, New Orleans, LA.

出版信息

Ochsner J. 2024 Fall;24(3):171-178. doi: 10.31486/toj.24.0013.

Abstract

Androgen deprivation therapy, the mainstay of treatment for patients with advanced prostate cancer, can be either medical or surgical. Surgery has cost benefits compared to medical treatment. In this study, we evaluated the use of simple and epididymal-sparing orchiectomy in 2 different practice settings for the treatment of metastatic prostate cancer. We reviewed patients who underwent surgical castration for metastatic prostate cancer between 2011 and 2022. The primary outcome was achieving castration-level total testosterone of <50 ng/dL. We also compared the characteristics of patients who were seen at a public academic teaching hospital vs those who were seen at a private community hospital (oncology group practice), and we evaluated the impact of orchiectomy approach (simple vs epididymal-sparing orchiectomy) on patient outcomes. We analyzed 101 patients who underwent orchiectomy: 40 (39.6%) at a public academic teaching hospital and 61 (60.4%) at a private community hospital (oncology group practice). Of these patients, 81 (80.2%) underwent simple orchiectomy and 20 (19.8%) underwent epididymal-sparing orchiectomy. Forty-nine patients (48.5%) had previously received medical androgen deprivation therapy, 9 (18.4%) of whom had medication adherence issues. Patient age, race, and marital status differed significantly between hospital facilities. The overall surgical complication rate was 3.0%. Postoperative total testosterone levels were available for 81 patients, drawn a median of 57 days after surgery [IQR 30, 123]. All patients had castrate-level total testosterone (median 10 ng/dL [IQR 9, 19]) postoperatively, with no differences seen between surgery location ( = 0.84) or surgical technique ( = 0.90). Simple or epididymal-sparing orchiectomy is safe and effective for surgical castration and is an alternative to medical androgen deprivation therapy for patients diagnosed with metastatic prostate cancer regardless of the practice demographics.

摘要

雄激素剥夺疗法是晚期前列腺癌患者的主要治疗方法,可分为药物治疗或手术治疗。与药物治疗相比,手术具有成本效益。在本研究中,我们评估了单纯睾丸切除术和保留附睾睾丸切除术在两种不同临床环境中用于治疗转移性前列腺癌的情况。我们回顾了2011年至2022年间接受手术去势治疗转移性前列腺癌的患者。主要结局是达到去势水平的总睾酮<50 ng/dL。我们还比较了在公立学术教学医院就诊的患者与在私立社区医院(肿瘤学集团诊所)就诊的患者的特征,并评估了睾丸切除术方法(单纯睾丸切除术与保留附睾睾丸切除术)对患者结局的影响。我们分析了101例接受睾丸切除术的患者:40例(39.6%)在公立学术教学医院,61例(60.4%)在私立社区医院(肿瘤学集团诊所)。在这些患者中,81例(80.2%)接受了单纯睾丸切除术,20例(19.8%)接受了保留附睾睾丸切除术。49例患者(48.5%)之前接受过药物雄激素剥夺治疗,其中9例(18.4%)存在药物依从性问题。医院机构之间患者的年龄、种族和婚姻状况存在显著差异。总体手术并发症发生率为3.0%。81例患者术后有总睾酮水平数据,术后中位数为57天采集样本[四分位间距30,123]。所有患者术后总睾酮水平均处于去势水平(中位数10 ng/dL[四分位间距9,19]),手术地点(P=0.84)或手术技术(P=0.90)之间未见差异。单纯睾丸切除术或保留附睾睾丸切除术对于手术去势是安全有效的,并且对于诊断为转移性前列腺癌的患者,无论临床人口统计学特征如何,都是药物雄激素剥夺疗法的一种替代方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb32/11398619/cd3db180b0e6/toj-24-0013-figure3.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验